

## A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05)

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- invasive triple negative breast cancer (TNBC) still remains in the breast or lymph nodes after therapy and surgery - unable to do physically strenuous activity but able to walk and carry out work of a light or sedentary nature, e.g., light house work, office work - see link to [clinicaltrials.gov](http://clinicaltrials.gov) for complete inclusion and exclusion criteria

---

**Exclusion Criteria:**

- Stage IV (metastatic) breast cancer or previous cancer in the same or other breast - evidence that the cancer has reoccurred after preoperative therapy and surgery - presence of germline breast cancer gene (BRCA) mutations

### Conditions & Interventions

**Conditions:**

Cancer

**Keywords:**

TNBC, Triple Negative Breast Cancer, Clinics and Surgery Center (CSC)

### More Information

**Description:** The purpose of this study is to see if sacituzumab govitecan in combination with pembrolizumab can improve outcomes and delay the return of disease in participants with high-risk early Triple Negative Breast Cancer (TNBC) when compared to pembrolizumab alone or pembrolizumab in combination with capecitabine. Participants with low tumor expression of the estrogen and/or progesterone receptors (1 to 10%) will also be included in this study. The study treatment will be chosen by chance—like flipping a coin. There is a 1 out of 2 chances to receive Sacituzumab govitecan in combination with Pembrolizumab and 1 out of 2 chances to receive a study treatment of study doctor's choice of either pembrolizumab alone or pembrolizumab in combination with capecitabine. Participants and their study doctor will know what study drug is being taken.

**Study Contact:** Anne Blaes - [blaes004@umn.edu](mailto:blaes004@umn.edu)

**Principal Investigator:** Anne Blaes, MD

**Phase:** PHASE3

**IRB Number:** STUDY00021239

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.